T Cell News and Research

Latest T Cell News and Research

Ortho Biotech submits NDA for Trabectedin in relapsed ovarian cancer

Ortho Biotech Products, L.P. has announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC).

20 Nov 2008

Scientists trick immune system of mice into believing transplanted islets are its own cells

The body's immune system hates strangers. When its security patrol spots a foreign cell, it annihilates it.

20 Nov 2008

Lactic acid found to be important energy source for tumor cells

Many tumors have cells that burn fuel for activities in different ways. Tumor cells near blood vessels have adequate oxygen sources and can either burn glucose like normal cells, or lactic acid (lactate). Tumor cells further from vessels are hypoxic and inefficiently burn a lot of glucose to keep going. In turn, they produce lactate as a waste product.

20 Nov 2008

Researchers reveal a new aspect of tumor development

The DNA in our cells is constantly under assault from oxygen, the sun's radiation and environmental stresses.

20 Nov 2008

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

New insight into the response of human skin to radiation

Scientists have new insight into the response of human skin to radiation and what drives the most aggressive and deadly form of skin cancer.

20 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

FDA strengthens safety of Sucraid (sacrosidase) oral solution

The U.S. Food and Drug Administration today issued an expedited approval of a supplemental application that allows for changes in the manufacturing of Sucraid (sacrosidase) Oral Solution.

20 Nov 2008

Bionovo to present phase 1B trial results of BZL101 in metastatic breast cancer

Bionovo, Inc. has announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia.

20 Nov 2008

LDL cholesterol inhibits the breakdown of peripheral fat

The so called bad cholesterol (LDL) inhibits the breakdown of fat in cells of peripheral deposits, according to a study from the Swedish medical university Karolinska Institutet.

20 Nov 2008

Targeted nanoparticles boost platinum-based anticancer therapy

A research team from the Massachusetts Institute of Technology (MIT)-Harvard Center for Nanotechnology Excellence has custom-designed nanoparticles that can deliver the anticancer drug cisplatin specifically to prostate cancer cells.

20 Nov 2008

Tissue Genesis applies CE Mark to tissue genesis cell isolation system

Tissue Genesis, Inc. has announced that effective immediately, the Tissue Genesis Cell Isolation System will be available to the European marketplace.

19 Nov 2008

New cell phone apps automatically track workouts and green transportation

Planning on gobbling a few extra treats this holiday season? Soon, your cell phone may be able to help you maintain your exercise routine and keep the pounds off over winter months, without your having to lift a finger to keep track.

19 Nov 2008

Survival of head and neck cancer patients is greatly affected by coexisting ailments

Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.

19 Nov 2008

Cytori announces seven new investigator-initiated clinical studies in Japan

All seven studies are investigator-initiated and to be performed under local and country guidelines. Cytori, who will not sponsor these studies, will continue work with country authorities, such as the Ministry of Health and Labor in Japan, to obtain specific regulatory approvals for its products.

19 Nov 2008

Marijuana may be good for the aging brain

The more research they do, the more evidence Ohio State University scientists find that specific elements of marijuana can be good for the aging brain by reducing inflammation there and possibly even stimulating the formation of new brain cells.

19 Nov 2008

Researchers identify best time for stem cell collection for Parkinson's therapy

Researchers have identified a stage during dopamine neuron differentiation that may be an ideal time to collect human embryonic stem cells for transplantation to treat Parkinson's disease, according to data presented at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience.

19 Nov 2008

More data released on key diabetes genes

One of the most reliable indicators to predict that a person will develop type 2 diabetes is the presence of insulin resistance.

19 Nov 2008

Prana Biotechnology's compound could halt Alzheimer's pathology

Prana Biotechnology has announced that a recent independent study conducted by Massachusetts General Hospital (MGH) has demonstrated that the Company's Metal-Protein Attenuating Compounds (MPACs) could halt Alzheimer's pathology.

19 Nov 2008

Phosphaplatins kill ovarian, testicular, head and neck cancer cells

A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences.

19 Nov 2008